Johannesburg-based BioInformatiCo takes second-place in an international AI challenge with African technology designed to accelerate clinical trial database preparation, improve data quality and help research teams make limited funding go further. Note to editors: You can access high-resolution images of Shirley Collie and the BioInformatiCo team here and a video of the CDISC AI Challenge here.
A South African-developed artificial intelligence (AI) platform designed to help researchers prepare clinical trial databases faster has placed second in the 2026 CDISC AI Innovation Challenge, earning international recognition for African-developed technology to address a key bottleneck in clinical research worldwide.
Created by Johannesburg-based clinical data management organisation BioInformatiCo, the platform called “Leova” automates aspects of building and testing the digital databases used to collect information during trials of new medicines and vaccines. By reducing the time and manual effort required to prepare these systems, the platform aims to help research teams identify database errors and protocol inconsistencies earlier and devote more resources to the research itself.
For Shirley Collie, Founder and CEO of BioInformatiCo, the global recognition is an important milestone for the company and a demonstration of how African-developed technology can contribute to clinical research globally: “Placing second in the CDISC AI Innovation Challenge is an important endorsement of what we have built. It shows that technology developed in Africa can help tackle challenges in clinical research worldwide, while supporting the continent’s ability to generate evidence that reflects the health needs of its own populations,” says Collie.
BioInformatiCo developed Leova within its existing clinical research operations, drawing on the practical demands of building reliable databases for clinical trials. The company currently supports first-in-human to Phase 3 vaccine research for infectious diseases, including HIV, TB, Ebola and COVID-19.
The global recognition from CDISC also comes at a time when US funding cuts have disrupted health programmes and medical research in South Africa, adding pressure to an already stretched research ecosystem. HIV programmes, clinical studies and research infrastructure have especially been affected,
while universities and research organisations face funding shortfalls and uncertainty over grants. In this environment, automating time-consuming manual work, such as building and testing a study database, can cut both hours and costs, helping limited resources go further. That is what Leova is designed to do.
“Before a new medicine or vaccine can reach patients, clinical trials must establish whether it is safe and effective. But before the first participant can enrol, researchers need reliable systems to collect and manage the study data. Building and validating these databases can take 10 to 20 weeks of specialist work, with each system tailored to the trial’s specific research protocol. Errors at this stage can compromise data quality, create costly rework and delay the trial,” adds Collie.
“Leova was born out of a real operational need. We understand the pressure clinical research teams face to deliver reliable data, meet demanding standards and make every Rand count. While automation cannot replace sustainable funding or specialist expertise, it can help research teams work more efficiently while maintaining the quality and reliability of clinical data,” adds Collie.
Unlike software providers that simply license a platform for customers to operate independently, BioInformatiCo combines Leova with specialist clinical data management support and human oversight. In one study, Leova reduced the testing and validation of a database from five days of specialist effort to one. It is a clear example of how the platform reduces the time and cost of validation and gets studies ready sooner, while maintaining the traceability and quality controls required in clinical research.
BioInformatiCo supports clinical trials across sub-Saharan Africa and is expanding internationally, with a US site launching soon and sponsor discussions under way in Europe and Australia. The company also plans to open a seed funding round in the coming months to support Leova’s next phase of development and commercial growth: “This is an exciting time for South African innovation. We’ve built Leova to solve a real challenge in clinical research, drawing on our experience on the ground in Africa. Now, we have an opportunity to take that expertise and technology to the world, helping research teams work more efficiently while strengthening Africa’s contribution to global health research. We’re looking forward to what comes next,” concludes Collie.
The 2026 CDISC AI Innovation Challenge was organised by the Clinical Data Interchange Standards Consortium (CDISC), a global non-profit organisation that develops standards for clinical research data. These standards help ensure that data can be collected, exchanged and submitted consistently, including for regulatory review by the US Food and Drug Administration (FDA).
The challenge attracted 50 competitive submissions from 30 organisations and individual entrants, placing African-developed technology alongside several leading global innovators. Leova placed second among 19 entries in Use Case 1, which focused on using AI-generated synthetic data to automate software testing, demonstrating the potential for African innovation to compete on an international stage.